Skip to main content

Table 1 Patient and tumor characteristics

From: Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study

No. of patients (%)

≤75 years 711 (57 %)

>75 years 538 (43 %)

Total 1249 (100 %)

Age,

median (range), years

  

74 (21–99)

Sex, no. of patients (%)

 Male

418 (59 %)

266 (49 %)

684 (55 %)

 Female

293 (41 %)

272 (51 %)

565 (45 %)

ECOG performance, no. of patients (%)

 0

224 (32 %)

111 (22 %)

335 (28 %)

 1

350 (50 %)

281 (55 %)

631 (52 %)

 2

107 (15 %)

105 (20 %)

212 (18 %)

 3

12 (2 %)

18 (3 %)

30 (2 %)

 4

1 (0 %)

0 (0 %)

1 (0 %)

Grading, no. of patients (%)

 G0/G1

23 (3 %)

15 (3 %)

38 (4 %)

 G2

413 (62 %)

323 (66 %)

736 (64 %)

 G3

201 (30 %)

129 (26 %)

330 (29 %)

 GX

27 (4 %)

21 (4 %)

48 (4 %)

Disease site at entry, no. of patients (%)a

 Local

325 (46 %)

259 (48 %)

584 (47 %)

 Liver

453 (64 %)

352 (65 %)

805 (64 %)

 Lung

230 (32 %)

135 (25 %)

365 (29 %)

 Bone

30 (4 %)

24 (4 %)

54 (4 %)

 CNS

6 (1 %)

2 (0 %)

8 (1 %)

 Pleural effusion

16 (2 %)

9 (2 %)

25 (2 %)

 Ascites

21 (3 %)

24 (4 %)

45 (4 %)

 Other

151 (21 %)

95 (18 %)

246 (20 %)

Relapse-free intervalb, median, years n = 541 patientsc

1.8

1.5

1.6

M1 at initial diagnosis, no. of patients (%)

n = 1066 patientsc

367 (59 %)

279 (63 %)

646 (61 %)

Previous surgery, no. of patients (%)

n = 1248 patientsc

626 (88 %)

480 (89 %)

1106 (89 %)

Previous radiotherapy, no. of patients (%)

n = 1239 patientsc

137 (19 %)

53 (10 %)

190 (15 %)

Previous (neo) adjuvant chemo- therapy, no. of patients (%)

n = 847 patientsc

187 (37 %)

65 (19 %)

252 (30 %)

  1. athe choice of multiple categories was possible
  2. bpatients with metachronous metastases only
  3. cevaluable patients for the respective parameter